SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Precigen shares are trading higher after the company announced the first patient has been dosed its Phase I/II study of PRGN-2009 to treat HPV-associated cancers.

Benzinga · 08/17/2020 15:50